And Huang Pharmaceutical Hong Kong stock listing: one hand signing rate of 60%, priced at HK$40.1
Hehuang Pharmaceutical announced the results of the prospectus, issued 104 million shares, each share was priced at 40.1 yuan, each lot was 500 shares, the first hand signing rate was 60%, and the application for 80 lots won 1 lot. The shares are expected to be listed tomorrow. Hehuang Pharma received 21,100 valid applications in the Hong Kong public offering, with a total subscription of about 67.9945 million shares, an oversubscription of about 4.23 times, and the proportion of the public offering remained 12.5%. The international offering was oversubscribed by 4 times. The company is a global biopharmaceutical company owned by Changhe 44.66% and has been listed in the United States and the United Kingdom, after the listing, Li Ka-shing is the largest shareholder of Hehuang Pharmaceutical, Changhe will hold 39.2% of the shares of Hehuang Pharmaceutical, the company's directors hold 2.1%, and the public shareholders hold 58.7%. HMC Hutchison, CKHGI, Hutchison Whampoa China and HHHL will each remain controlling shareholders.
Ping An Insurance has a lot of money! Spent $46.7 billion to buy a number of property stakes in Singaporean real estate developers
Recently, according to Forbes, Singapore CapitaLand will sell part of its six integrated shopping and office real estate portfolios in China to Ping An Life for RMB46.7 billion. CapitaLand is a well-known diversified real estate conglomerate in Asia, headquartered in Singapore. Its Group operates in more than 230 cities in more than 30 countries around the world, with Singapore and China as its core markets. CapitaLand entered China in 1994 with the first project, Shanghai Baiteng Tower, in 1998, Ascott's first serviced residence opened in Shanghai, introducing the concept of serviced residence to China for the first time, and in 2004, the first Raffles City in China was born in Shanghai, and Raffles City officially entered China. It can be said that CapitaLand's entry into China began in Shanghai, and since then, CapitaLand group has been deeply involved in the Chinese market, and has achieved great development and growth. CapitaLand said the deal with Ping An is expected to close in the third quarter of this year, which will generate US$1.5 billion in net income for CapitaLand. After the reduction, 12.6% to 30% of the shares of Raffles City Shopping Centres in Beijing, Chengdu, Hangzhou, Ningbo and Shanghai will be retained. It will also continue to provide asset management services for these properties and earn fee income.
Overseas Chinese in France congratulated Cai Hanzhong, president of the Teochew Association in France, on his 90th birthday
On June 28th, the French Chaozhou Association held a celebration banquet at the Chinatown Restaurant in Paris to congratulate the president of the association, Cai Hanzhong, on his 90th birthday. On behalf of the Chinese Embassy in France, Senator Gao Ping and Li Chengyuan of the Consular and Overseas Chinese Affairs Office of the Chinese Embassy in France expressed their good wishes for President Cai Hanzhong with a pot of phalaenopsis orchids. Chen Wenxiong, member of the French National Assembly and chairman of the Franco-Chinese Friendship Group, Chen Kewei, permanent honorary president of the French Teochew Association, Zheng Hui, president of the French Chinese Mutual Aid Association, Jin Linze, executive chairman of the French Overseas Chinese Association, and other representatives of overseas Chinese circles in France and members of the French Teochew Association attended the meeting to congratulate the meeting.
Tencent's brand value has increased by nearly 400 billion yuan in three years, ranking fifth in the world
Tencent's stock price is approaching the low point of the year, but the brand value has increased by leaps and bounds. Recently, the 2021 Kantar BrandZ Most Valuable Global Brand Ranking was released in Cannes, and 18 brands in China were listed in the top 100 of the world's most valuable brands, becoming the second most expensive brand in the list for two consecutive years, contributing a total of 14% of the value of the world's top 100 brands. Among them, in the list of the world's top ten brands, Tencent once again ranked among the top five in the world, and its brand value ranking was higher than its market capitalization ranking. According to the latest global listed company market capitalization, Tencent ranks seventh in the world. According to the report, Tencent's brand value increased by 60%, much higher than the average value increase of 42% of the world's top 100 brands. The Reporter of Changjiang Business Daily noted that compared with the increase of Tencent's brand value by nearly 400 billion yuan three years ago, the growth part alone is equivalent to 1.3 Suning Tesco. Behind such a rapid rise is the good progress of Tencent's diversified business and the new force that contributes to profit performance.
Zhongguancun and Sichuan University signed a letter of intent to transfer the total synthesis technology of morphine drugs
On the evening of June 28, Zhongguancun issued an announcement signing a letter of intent with Sichuan University on the transfer of morphine drug total synthesis technology, and Sichuan University promised to synthesize morphine-related technologies and patents based on non-morphine substances as the starting material, and only cooperated exclusively with the company or the company's designated party. According to the announcement, the subject of the transfer is the platform technology for the synthesis of morphine drugs by non-morphine compounds as the initial substances for the synthesis of morphine drugs, including but not limited to relevant synthesis methods, synthetic routes, catalysts and related patents. The technology has been patented by China and accepted by the State Intellectual Property Office, and is still in the process of examination. Sichuan University said it will continue to promote the synthesis of oxycodone, codeine, and other drugs that use this as a starting material or intermediate according to the company's needs.
Contracted sales of HK$16.149 billion in FY2021 Gross margin of 43.7%
On June 28, China South City Holdings Limited announced its annual results for the year ended 31 March 2021. The announcement discloses that for the year ended 31 March 2021, Contract sales in South China City increased by HK$16,149 million, an increase of 19.5% year-on-year; revenue of HK$11,309 million, an increase of 14.4% year-on-year; gross profit margin of 43.7%; and net profit attributable to owners of the parent company of HK$2,415 million, a decrease of 8.3% year-on-year. In terms of debt structure, offshore, China South City issued US$125 million more senior notes in June 2020, US$200 million in Senior Notes in August 2020, US$250 million in Senior Notes in September 2020, US$120 million in Senior Notes in January 2021, and US$175 million in Senior Notes and US$50 million in March 2021.
Qixin Group participated in the bidding for the state-owned land use rights of Xin'an Street in Bao'an District
Qixin Group issued an announcement that the Company held the 12th meeting of the Seventh Board of Directors on June 28, 2021, deliberated and passed the "Proposal on Participating in the Bidding for the Right to Use the State-owned Land in Xin'an Street, Bao'an District", and agreed that the Company would participate in the listing and bidding of the commercial land use right of the parcel number A002-0082 (hereinafter referred to as the "Target Land") in Xin'an Street, Bao'an District, Shenzhen with its own or self-financing funds, and the Company would develop and construct the Qixin Bao'an Enterprise Headquarters Building on the target land. The Board of Directors authorizes the Chairman and General Manager of the Company to participate in the bidding for the land use right at a price within the scope of the board's decision-making authority. The Board of Directors authorized the bidding for land at the starting price of the listing, i.e. RMB665 million. If the bidding is successful, the chairman of the board of directors or his designated agent is authorized to handle the relevant procedures and sign relevant documents (including but not limited to the "Confirmation of Transaction", "Transfer Contract", etc.).
Diamond Glass: 832 million yuan plans to invest 832 million yuan for solar cell and module projects
Diamond Glass announced on the evening of June 28 that the company decided to invest in the construction of a 1.2GW large-size half-piece ultra-high-efficiency heterojunction solar cell and module project with a wholly-owned subsidiary, Wujiang Diamond Glass Technology Co., Ltd., as the main body of the implementation, hoping to further extend the company's photovoltaic product business chain and expand new performance growth points by actively laying out the heterojunction solar cell and module product market. The total amount of foreign investment is 832 million yuan, and the investment and construction period is 8 months. Diamond Glass said that China's photovoltaic industry has grown rapidly and established a solid solar photovoltaic cell manufacturing industry chain. This foreign investment can promote the company's business to produce synergy effects, enhance the company's profit points, improve the company's core competitiveness such as the technical level, automation level, cost control and other core competitiveness of the company's related product manufacturing, expand the company's photovoltaic products in the national market, and have a certain positive impact on the company's performance.
China Biopharmaceutical Drugs for the Treatment of Hepatitis B obtained a certificate of registration
China Biopharmaceuticals announced that the Group's new drug for the treatment of hepatitis B, "Propofol tenofovir fumarate tablets" (trade name: Qinglide), has been issued a drug registration certificate by the State Drug Administration of the People's Republic of China. This variety is declared according to 3 categories of chemicals and is deemed to have passed the consistency evaluation of the quality and efficacy of generic drugs; the approved indication is for the treatment of compensatory chronic hepatitis B virus infection in adults.
Guangzhou Pharmaceutical Group purchased more than one million yuan of Conghua lychee
Recently, Conghua lychee harvest. The reporter learned from the Guangzhou Pharmaceutical Group that recently, the Guangzhou Pharmaceutical Group and the Conghua District Government jointly held the activity of "purchasing conghua lily and promoting rural revitalization" of the Guangzhou Pharmaceutical Group, signed a lychee purchase agreement on the spot, ordered more than 17,000 boxes of conghua lychees, a total of more than 1.7 million yuan, and planned to copy the "lemon ji model" to help Guizhou to help the development of the conghua lychee industry. At the signing ceremony of the lychee order, Guangzhou Pharmaceutical Group signed a lychee procurement agreement with Liboyuan conghua and held a ceremony for the purchase of lychees from Guangzhou Pharmaceutical. It is reported that the purchase of lychees by Guangzhou Pharmaceutical Group for more than one million yuan will mainly give full play to the advantages of Guangzhou Pharmaceutical channels, sell for fruit farmers and for the welfare of employees, and promote consumption poverty alleviation.